Company Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases.
The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey.
The company is headquartered in Hackensack. New Jersey.
Country | United States |
Founded | 1993 |
IPO Date | May 15, 1998 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 213 |
CEO | Dror Bashan |
Contact Details
Address: 2 University Plaza, Suite 100 Hackensack, New Jersey 07601 United States | |
Phone | 201 696 9345 |
Website | protalix.com |
Stock Details
Ticker Symbol | PLX |
Exchange | NYSEAMERICAN |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001006281 |
CUSIP Number | 74365A309 |
ISIN Number | US74365A3095 |
Employer ID | 65-0643773 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dror Bashan | President, Chief Executive Officer and Director |
Eyal Rubin M.B.A. | Senior Vice President, Chief Financial Officer, Treasurer and Corporate Secretary |
Yaron Naos B.Sc., MBA | Senior Vice President of Operations |
Yael Fellous | Vice President of Human Resources |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 9, 2025 | 10-Q | Quarterly Report |
May 9, 2025 | 8-K | Current Report |
May 8, 2025 | ARS | Filing |
Apr 30, 2025 | DEF 14A | Other definitive proxy statements |
Apr 28, 2025 | S-3 | Registration statement under Securities Act of 1933 |
Apr 23, 2025 | 8-K | Current Report |
Mar 17, 2025 | 8-K | Current Report |
Mar 17, 2025 | 424B5 | Filing |
Mar 17, 2025 | 10-K | Annual Report |
Mar 17, 2025 | 8-K | Current Report |